Xin Sun

Xin Sun

Direktör/Styrelseledamot på EVEREST MEDICINES LIMITED
45 år
Health Technology
Consumer Services
Finance

Profil

Xin Sun is currently Chairman-Supervisory Board at Scivita Medical Technology Co., Ltd. since 2021.
Mr. Sun is Non-Executive Director at MicroPort Cardiac Rhythm Management International Ltd. since 2023, Everest Medicines Ltd. since 2025, and NeuroGen Pharma Ltd. since 2026.
Mr. Sun is Managing Director at CBC Group Co., Ltd. and Hillhouse Capital Management Co Ltd since 2017.
Mr. Sun is also a Research Associate at Genentech, Inc. Former roles include Non-Executive Director at Luye Pharma Group Ltd. from 2021 to 2023, Non-Executive Director at Shanghai MicroPort MedBot (Group) Co., Ltd. from 2021 to 2023, and Vice President at Affinity Equity Partners (HK) Ltd. Education includes undergraduate degrees from Peking University in 2003 and The Trustees of Columbia University in The City of New York in 2013, a graduate degree from Duke University in 2006, and an MBA from Columbia Business School.

Aktiva positioner av Xin Sun

FöretagPositionStart
EVEREST MEDICINES LIMITED Direktör/Styrelseledamot 2025-12-11
Ordförande 2021-06-22
Direktör/Styrelseledamot 2020-07-17
CBC Group Co., Ltd.
Företagsledare/Principal -
Företagsledare/Principal 2017-01-01
Företagsledare/Principal -

Tidigare kända positioner av Xin Sun

FöretagPositionSlut
SHANGHAI MICROPORT MEDBOT (GROUP) CO., LTD. Direktör/Styrelseledamot 2023-12-29
LUYE PHARMA GROUP LTD. Direktör/Styrelseledamot 2023-12-06
Företagsledare/Principal -
Se detaljerna i Xin Suns erfarenhet

Xin Suns utbildningar

Erfarenheter
Innehade positioner

Aktiva

Inaktiva

Börsnoterade företag

Privata företag

Relationer

97

Första gradens relationer

13

Företag kopplade till första graden

Man

Kvinna

Styrelseledamöter

Chefer

Kopplade företag

Privata företag13

Health Technology

Consumer Services

Consumer Services

Consumer Services

Finance

Health Technology

Consumer Services

Health Technology

CBC Group Co., Ltd.

Health Technology

Health Technology

Miscellaneous

Finance